GPCR
NASD Structure Therapeutics, Inc. Sponsored ADR$25.54 ↑ +0.00 (+0.00%) Trading Up from the previous close of $25.54, $0.61 below the day’s high of $26.15
- YTD change
- -63.28%
- vs 20-day SMA
- -23.34%
- vs 200-day SMA
- -51.64%
Price ranges
Price & Performance
-28.97 (-53.15%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 73.1% away from all-time highs of $94.90
- GPCR is down 63% since the beginning of the year
- GPCR is down 16% over the past 12 months
- GPCR is down 35% over the past 1 month
- 4% of all GPCR investors are betting against GPCR
GPCR reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -15.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.02
- Last 5 days
- -11.87%
- vs 8-day SMA
- -10.39%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
